Search PubMedSearch

PubMed · 8216728

[The complement system].

Abstract

After its discovery, about 100 years ago, complement was described as a cytotoxicity effector, the "armed hand" of antibodies. Since the description of an "alternate" pathway of activation, independent of antigen-antibody reactions, this restrictive concept has been modified. It has been progressively revealed to be a system that is composed of many proteins and our understanding of their biological roles has become much more developed. Nowadays, it is especially considered as a means for the body to generate peptides that regulate many functions: phagocytosis, antibody synthesis, inflammatory reactions, photosensitisation, coagulation, etc. Discovery of components, not only in the vehicles of serum or the other biological fluids but also associated with the cell membrane, has greatly increased the regions of action. Finally, progress in genetics, particularly in nucleic acid sequencing, has revealed families of proteins, a priori not apparent, that are analogues of the sequences and take part in the function of very varied areas. The roles of complement are thus not restricted only to immunological mechanisms, but they extend into many areas of biology and physiology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Lambré. 1993. [The complement system].. https://pubmed.ncbi.nlm.nih.gov/8216728/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Quartz crystal microbalance detection of Vibrio cholerae O139 serotype.

A piezoelectric (PZ) quartz crystal microbalance (QCM) biosensor for the rapid detection of Vibrio cholerae serotype O139 has been developed. The antibody to this serotype was immobilized on the gold transducer surface of a 10 MHz AT cut PZ crystal. Solutions containing known antigen concentrations were then incubated for 1 h on the antibody-bound transducer. The biosensor was able to detect 10(5) cells per ml of O139 versus a background of O1 (Ogawa) serotype.

Antigen-Antibody Reactions

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

In the tumor-bearing host, T cells invariably fail to induce a clinically significant antitumor immune response. Although model systems support the existence of tumor peptide antigens, the molecular interactions critical for antigen presentation by the tumor cell remain unresolved. Here, we demonstrate that human follicular lymphoma cells are highly inefficient at presenting alloantigen despite their strong expression of major histocompatibility complex and low-to-intermediate expression of some adhesion and B7 costimulatory molecules. Activation of follicular lymphoma cells via CD40 induces or up-regulates both adhesion and B7 costimulatory molecules essential to repair this defect. More importantly, once primed, alloreactive T cells efficiently recognize unstimulated follicular lymphoma cells. Thus, correction of defective tumor immunity requires not only expression of major histocompatibility complex but also sufficient expression of multiple adhesion and costimulatory molecules.

Antigen-Antibody Reactions

Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro.

Fas antigen (CD95) can induce apoptosis of cells such as lymphocytes and neutrophils. To determine whether Fas antigen is involved in eosinophil apoptosis, we examined its expression and function on eosinophils in vitro. Purified human eosinophils expressed low but consistently detectable levels of Fas antigen. Culture of eosinophils in up to 10 ng/mL interleukin-5 (IL-5) prolonged eosinophil survival; incorporation of 1 to 1,000 ng/mL Fas antibody led to significant reductions in IL-5-induced eosinophil viability after 48 to 72 hours of culture. Reductions in survival could not be overcome by IL-5 and also occurred in the absence of exogenous IL-5. Preactivation of eosinophils with platelet-activating factor (PAF) significantly reduced eosinophil viability without altering the survival-reducing effects of Fas antibody treatment. In contrast, RANTES did not affect eosinophil viability or Fas antibody-induced reductions in eosinophil survival. After treatment with Fas antibody, electron microscopy of eosinophils and gel electrophoresis of DNA extracted from eosinophils demonstrated changes consistent with apoptosis. These data demonstrate that Fas antigen can modify eosinophil survival by inducing apoptosis through a pathway that is, at least in part, independent of the survival-promoting effects of IL-5.

Antigen-Antibody Reactions